Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[WT1 peptide-based immunotherapy].

Haruo Sugiyama¹

¹Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|June 14, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.

Blood advances·2026

Same author

Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.

European journal of cancer (Oxford, England : 1990)·2026

Same author

WT1-pulsed dendritic cell vaccination for neovascular age-related macular degeneration: a phase I pilot feasibility study.

BMC ophthalmology·2026

Same author

RNA-based co-transfer of human CD8αβ with WT1-specific TCRαβ redirects tumor recognition by CD4 and γδ T-cells towards MHC class I-restricted WT1 epitopes and boosts CD8 T-cell responses with or without CD3 mRNA.

Experimental hematology & oncology·2026

Same author

Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine.

Journal for immunotherapy of cancer·2025

Same author

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Journal of hematology & oncology·2025

Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019

See all related articles

Wilms' tumor gene WT1 is overexpressed in cancers. WT1 peptide immunotherapy showed promising clinical responses and suggests potential for future cancer treatments.

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

The Wilms' tumor gene (WT1) is frequently overexpressed in various hematologic malignancies and solid tumors.
WT1 protein functions as a tumor rejection antigen, making it a potential target for cancer immunotherapy.

Observation:

Phase I clinical trials investigated WT1 peptide-based cancer immunotherapy.
The trials observed positive clinical responses in patients.

Findings:

While effective, the immunotherapy primarily resulted in localized skin reactions at the vaccine injection sites.
These findings indicate the immunogenicity of the WT1 vaccine.

Implications:

WT1-targeting immunotherapy demonstrates promise as a viable strategy for treating WT1-expressing cancers.

Related Experiment Videos

Further research and development of WT1-based vaccines could lead to improved cancer treatment options.